BioSpace News Archive

Curis, Inc. today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences.

Lineage Cell Therapeutics, Inc. today announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company’s exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc.

TransMed7, LLC announced the first sales of Concorde ) Soft Tissue Biopsy devices, to the Margaret West Comprehensive Breast Center in Germantown, TN.

Kriya Therapeutics, Inc. today announced that it has acquired Tramontane Therapeutics, Inc. (“Tramontane”).

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced its participation in the upcoming investor conferences.

Cerevance today announced Craig Thompson, chief executive officer (CEO) and Johnna Simões, vice president, corporate development, will participate in panel discussions during the 6th Annual LSX World Congress USA being held in Boston, MA, September 13-14th.

NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET.

Neurophth Therapeutics, a leader in in-vivo gene therapy for ophthalmic diseases in China, announced the Australian Therapeutic Goods Administration has registered and approved its candidate drug, NFS-05, for clinical trials targeting Autosomal Dominant Optic Atrophy.

Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, announced it has named Ron Andrews as its Non-Executive Chair.